In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes

Affiliations

Comment

Sotirios Tsimikas. J Lipid Res. 2018 May.

. 2018 May;59(5):741-744.

doi: 10.1194/jlr.C085639. Epub 2018 Apr 2.

¹ Division of Cardiovascular Diseases, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA stsimikas@ucsd.edu.

No abstract available

Comment on

LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk.
Mu-Han-Ha-Li 迪丽达尔木汗哈力 DL, Zhai 翟天羽 TY, Ling 凌雁 Y, Gao 高鑫 X. Mu-Han-Ha-Li 迪丽达尔木汗哈力 DL, et al. J Lipid Res. 2018 May;59(5):884-891. doi: 10.1194/jlr.P082792. Epub 2018 Mar 6. J Lipid Res. 2018. PMID: 29511049 Free PMC article.

1. Mora S., Kamstrup P. R., Rifai N., Nordestgaard B. G., Buring J. E., and Ridker P. M.. 2010. Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 56: 1252–1260. - PMC - PubMed
1. Kamstrup P. R., and Nordestgaard B. G.. 2013. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 1: 220–227. - PubMed
1. Ye Z., Haycock P. C., Gurdasani D., Pomilla C., Boekholdt S. M., Tsimikas S., Khaw K. T., Wareham N. J., Sandhu M. S., and Forouhi N. G.. 2014. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes. 63: 332–342. - PMC - PubMed
1. Kaya A., Onat A., Yuksel H., Can G., Yuksel M., and Ademoglu E.. 2017. Lipoprotein(a)-activated immunity, insulin resistance and new-onset diabetes. Postgrad. Med. 129: 611–618. - PubMed
1. Paige E., Masconi K. L., Tsimikas S., Kronenberg F., Santer P., Weger S., Willeit J., Kiechl S., and Willeit P.. 2017. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc. Diabetol. 16: 38. - PMC - PubMed